Unique challenges required reassessment and alterations to critical reagents to rescue a neutralizing antibody assay

References

• Wadhwa M, Knezevic I, Kang HN, et al. Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility. Biologicals. 2015;43(5):298–306. doi:10.1016/j.biologicals.2015.06.004
   PubMed Web of Science ®Google Scholar
• Porter S. Human immune response to recombinant human proteins. J Pharm Sci. 2001;90(1):1–11. doi:10.1002/1520-6017(200101)90:1<1::aid-jps1>3.0.co;2-k
   PubMed Web of Science ®Google Scholar
• Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1–2):1–16. doi:10.1016/j.jim.2004.06.002
   PubMed Web of Science ®Google Scholar
• Gupta S, Indelicato SR, Jethwa V, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods. 2007;321(1–2):1–18. doi:10.1016/j.jim.2006.12.004
   PubMed Web of Science ®Google Scholar
• Tatarewicz SM, Mytych DT, Manning MS, et al. Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. Bioanalysis. 2014;6(11):1509–1523. doi:10.4155/bio.14.114
   PubMed Web of Science ®Google Scholar
• Gunn G III, Sealey DC, Jamali F, et al. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. Clin Exp Immunol. 2016;184(2):137–146. doi:10.1111/cei.12742
   PubMed Web of Science ®Google Scholar
• Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2003;18(7):1257–1259. doi:10.1093/ndt/gfg164
   PubMed Web of Science ®Google Scholar
• Mok C, Van Der Kleij D, Wolbink G. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429–1435. doi:10.1007/s10067-013-2336-x
   PubMed Web of Science ®Google Scholar
• Gorovits B, Wakshull E, Pillutla R, et al. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J Immunol Methods. 2014;408:1–12. doi:10.1016/j.jim.2014.05.010
   PubMed Web of Science ®Google Scholar
• Gouty D, Cai C, Cai X, et al. Recommendations for the development and validation of neutralizing antibody assays in support of biosimilar assessment. AAPS J. 2018;20(1):25. doi:10.1208/s12248-017-0181-6
   Web of Science ®Google Scholar
• Wu B, Chung S, Jiang X-R, et al. Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. AAPS J. 2016;18(6):1335–1350. doi:10.1208/s12248-016-9954-6
   PubMed Web of Science ®Google Scholar
• Patton A, Mullenix MC, Swanson SJ, et al. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods. 2005;304(1–2):189–195. doi:10.1016/j.jim.2005.06.014
   PubMed Web of Science ®Google Scholar
• Sickert D, Kroeger K, Zickler C, et al. Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore. J Immunol Methods. 2008;334(1–2):29–36. doi:10.1016/j.jim.2008.01.010
   PubMed Web of Science ®Google Scholar
• Carle K, Kellie JF, Gunn GR, et al. Determination of label efficiency and label degree of critical reagents by LC-MS and native MS. Anal Biochem. 2023;664:115033. doi:10.1016/j.ab.2022.115033
   PubMed Web of Science ®Google Scholar
• Jiang Y, Mayer AP, Carle K, et al. Simple method to determine the concentration and incorporation ratio of ruthenium-labeled antibodies. Bioanalysis. 2021;14(1):19–28. doi:10.4155/bio-2021-0197
   PubMed Web of Science ®Google Scholar
• Gupta S, Devanarayan V, Finco D, et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal. 2011;55(5):878–888. doi:10.1016/j.jpba.2011.03.038
   PubMed Web of Science ®Google Scholar
• Devanarayan V, Smith WC, Brunelle RL, et al. Recommendations for systematic statistical computation of immunogenicity cut points. AAPS J. 2017;19:1487–1498. doi:10.1208/s12248-017-0107-3
   PubMed Web of Science ®Google Scholar
• Dennler P, Fischer E, Schibli R. Antibody conjugates: from heterogeneous populations to defined reagents. Antibodies. 2015;4:197–224. doi:10.3390/ANTIB4030197
   Web of Science ®Google Scholar
• Gautier V, Boumeester AJ, Lössl P, et al. Lysine conjugation properties in human IgGs studied by integrating high-resolution native mass spectrometry and bottom-up proteomics. Proteomics. 2015;15(16):2756–2765. doi:10.1002/pmic.201400462
   PubMed Web of Science ®Google Scholar
• Lalonde M-E, Durocher Y. Therapeutic glycoprotein production in mammalian cells. J Biotechnol. 2017;251:128–140. doi:10.1016/j.jbiotec.2017.04.028
   PubMed Web of Science ®Google Scholar
• Goh JB, Ng SK. Impact of host cell line choice on glycan profile. Crit Rev Biotechnol. 2018;38(6):851–867. doi:10.1080/07388551.2017.1416577
   PubMed Web of Science ®Google Scholar
• Olovnikova N, Grigorieva O, Petrov A. Effector properties and glycosylation patterns of recombinant human anti-D-IgG1 antibodies produced by human PER. C6™ cells Bulletin Exp Biol Med. 2012;154:245–249. doi:10.1007/s10517-012-1923-1
   PubMed Web of Science ®Google Scholar
• Blundell PA, Lu D, Dell A, Haslam SM, et al. Choice of host cell line is essential for the functional glycosylation of the fragment crystallizable (Fc) region of human IgG1 inhibitors of influenza B viruses. J Immunol. 2019;204(4):1022–1034. doi:10.4049/jimmunol.1901145
   Web of Science ®Google Scholar